Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's epilepsy "brain pacemaker" meets early trial:

This article was originally published in Clinica

Executive Summary

Medtronic's epilepsy "brain pacemaker" for reducing seizures in patients with a difficult-to-treat form of the condition could become commercially available in the US in 2008, said the company, which noted that its pivotal clinical trial for the device - called Intercept - had met an early milestone. Some 15 sites in the US are participating in the study and over half of all patients needed to complete the trial are already enrolled. Medtronic said that epilepsy has been estimated to affect 2.7 million people in the US and 50 million individuals worldwide. Despite trying a range of treatment options, around one-third of patients continue to experience debilitating, recurring seizures or brief periods of abnormal electrical activity in the brain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056900

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel